Anti-angiogenic effects of the DPP-4 inhibitor linagliptin via inhibition of VEGFR signalling in the mouse model of oxygen-induced retinopathy

Knockdown of CXCR4 Inhibits CXCL12-Induced Angiogenesis in HUVECs through Downregulation of the MAPK/ERK and PI3K/AKT and the Wnt/β-Catenin Pathways

(2018) Zhi-Yu Song et al.   CANCER INVESTIGATION

Glucagon-like peptide-1 receptor expression in the human eye

(2018) Josephine B. Hebsgaard et al.   DIABETES OBESITY & METABOLISM

Retinal vasculature development in health and disease

(2018) Senthil Selvam et al.   PROGRESS IN RETINAL AND EYE RESEARCH

Sitagliptin Accelerates Endothelial Regeneration after Vascular Injury Independent from GLP1 Receptor Signaling

(2018) Friederike Remm et al.   Stem Cells International

SEMA3A partially reverses VEGF effects through binding to neuropilin-1

(2017) Bruna Palodetto et al.   Stem Cell Research

Effects of linagliptin and liraglutide on glucose- and angiotensin II-induced collagen formation and cytoskeleton degradation in cardiac fibroblasts in vitro

(2016) Xian-wei Wang et al.   ACTA PHARMACOLOGICA SINICA

Modulation of myocardial injury and collagen deposition following ischaemia-reperfusion by linagliptin and liraglutide, and both together

(2016) X. Wang et al.   CLINICAL SCIENCE

DPP-4 Inhibition by Linagliptin Attenuates Obesity-Related Inflammation and Insulin Resistance by Regulating M1/M2 Macrophage Polarization

(2016) Fen Zhuge et al.   DIABETES

Synergic effects of VEGF-A and SDF-1 on the angiogenic properties of endothelial progenitor cells

(2016) Gabriela Odent Grigorescu et al.   Journal of Tissue Engineering and Regenerative Medicine

Dipeptidyl peptidase-4 inhibitor, linagliptin, ameliorates endothelial dysfunction and atherogenesis in normoglycemic apolipoprotein-E deficient mice

(2016) Hotimah Masdan Salim et al.   VASCULAR PHARMACOLOGY

The DPP4 Inhibitor Linagliptin Protects from Experimental Diabetic Retinopathy

(2016) Nadine Dietrich et al.   PLoS One

Dipeptidyl Peptidase-4 Inhibitor Increases Vascular Leakage in Retina through VE-cadherin Phosphorylation

(2016) Choon-Soo Lee et al.   Scientific Reports

Glucagon-Like Receptor 1 Agonists and DPP-4 Inhibitors: Potential Therapies for the Treatment of Stroke

(2015) Vladimer Darsalia et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

Establishment of a dipeptidyl peptidases (DPP) 8/9 expressing cell model for evaluating the selectivity of DPP4 inhibitors

(2015) Yi Huan et al.   JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS

Microglia and Interleukin-1β in Ischemic Retinopathy Elicit Microvascular Degeneration Through Neuronal Semaphorin-3A

(2013) José Carlos Rivera et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Neuron-Derived Semaphorin 3A Is an Early Inducer of Vascular Permeability in Diabetic Retinopathy via Neuropilin-1

(2013) Agustin Cerani et al.   Cell Metabolism

Regulation of angiogenesis by PI3K signaling networks

(2013) Mariona Graupera et al.   EXPERIMENTAL CELL RESEARCH

VEGFR and Type-V RTK Activation and Signaling

(2013) M. Shibuya   Cold Spring Harbor Perspectives in Biology

Diabetic Retinopathy: Targeting Vasoregression

(2010) H.-P. Hammes et al.   DIABETES

Stromal cell-derived factors 1α and 1β, inflammatory protein-10 and interferon-inducible T cell chemo-attractant are novel substrates of dipeptidyl peptidase 8

(2008) Katerina Ajami et al.   FEBS LETTERS

(R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a Novel Xanthine-Based Dipeptidyl Peptidase 4 Inhibitor, Has a Superior Potency and Longer Duration of Action Compared with Other Dipeptidyl Peptidase-4 Inhibitors

(2008) L. Thomas et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Dipeptidyl peptidase-IV enzymatic activity bearing molecules in human brain tumors - good or evil?

(2007) Petr Busek   Frontiers in Bioscience-Landmark